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Abstract
Because of the shifted focus in life science research from genome analyses to genetic and protein function
analyses, we now know functions of numerous proteins. These analyses, including those of newly identified
proteins, are expected to contribute to the identification of proteins of therapeutic value in various diseases.
Consequently, pharmacoproteomic-based drug discovery and development of protein therapies attracted a great
deal of attention in recent years. Clinical applications of most of these proteins are, however, limited because of
their unexpectedly low therapeutic effects, resulting from the proteolytic degradation in vivo followed by rapid
removal from the circulatory system. Therefore, frequent administration of excessively high dose of a protein is
required to observe its therapeutic effect in vivo. This often results in impaired homeostasis in vivo and leads to
severe adverse effects. To overcome these problems, we have devised a method for chemical modification of
proteins with polyethylene glycol (PEGylation) and other water-soluble polymers. In addition, we have established a
method for creating functional mutant proteins (muteins) with desired properties, and developed a site-specific
polymer-conjugation method to further improve their therapeutic potency. In this review, we are introducing our
original protein-drug innovation system mentioned above.
Introduction
The success of the human genome project has clearly
shown that the human genome encodes about 35,000
genes and over half of them are poorly understood pro-
teins. A number of these proteins are thought to be
related to pathological disorders and other biological
phenomena, and thus, are potentially useful as therapeu-
tic agents and as targets for pharmaceutical develop-
ment. Therefore, focus in life science research has
currently shifted to newer fields, such as proteomics and
structural genomics, in which the function and structure
of proteins are analyzed en masse. Such analyses of large
number of proteins, including the newly identified pro-
teins, are expected to contribute to the identification of
proteins of therapeutic importance in various diseases.
In recent years, protein therapies using cytokines or
antibodies have attracted a great deal of attention.
Indeed, attempts are currently under progress to
develop a wide range of therapeutic proteins for treating
various diseases including cancer, hepatitis and autoim-
mune conditions[1-4]. Unfortunately, clinical applica-
tions of many of these proteins are limited because of
their unexpectedly poor therapeutic effects[5,6]. Often
these proteins are degraded by various proteases in vivo
and rapidly removed from the circulatory system. Con-
sequently, frequent administration of an excessively high
dose of a protein is required to obtain its desired thera-
peutic effect in vivo, leading to a disturbance in the
homeostasis and unexpected side effects. Additionally,
bioactive proteins, such as cytokines, generally show
pleiotropic actions through a number of receptors in
vivo, making it difficult to elicit the desired effect with-
out simultaneously triggering undesirable secondary
effects. From this standpoint, creation of novel technolo-
gies that overcome the problems peculiar to bioactive
proteins is essential for the advancement of pharmaco-
proteomic-based drug development. These technologies
are suitable as Drug Delivery Systems (DDSs), aiming to
maximize the therapeutic potency of proteins.
Our laboratory aims to develop novel DDS techniques
for overcoming the problems of protein therapy: (i)
establishment of a novel polymer-conjugation system to
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bioactive proteins (polymeric DDS) and (ii) development
of a powerful system to rapidly create functional mutant
proteins (muteins) with enhanced receptor affinity and
receptor specificity using a phage display technique (bio-
logical DDS). We are currently in the process of com-
bining both approaches to create a protein-drug
innovation system to further promote pharmaco-proteo-
mic-based drug development. In this review, we will
describe DDS-based technology to create functional
mutants for advanced medical applications using the
tumor necrosis factor-alpha (TNF) as an example and
the usefulness of site-specific polymer-conjugation of
proteins.
Bioconjugation as a polymeric DDS
One way to circumvent the problems of protein therapy
is to conjugate them with polyethylene glycol (PEG) and
other water-soluble polymeric modifiers (Figure 1)
[4,7,8]. The covalent conjugation of proteins with PEG
(PEGylation) increases their molecular size and steric
hindrance, both of which depend on the properties of
the PEG attached to the protein. Bioconjugation of pro-
teins decreases their renal excretion rate due to the
increased molecular size. In addition, because the poly-
mers cover the protein surface, attack by a protease is
generally blocked due to the steric hindrance, thus
p r o l o n g i n gt h eh a l f - l i f eo ft h ep r o t e i nin vivo.T h ep r o -
longed circulating lifetime in blood induces the
enhanced permeability and retention (EPR) effect, which
is based on the leaky nature of the tumor blood vessels,
resulting in increased delivery of the conjugates to the
tumor tissue[9]. Because of all these advantages, it is
possible to use the bioactive protein at a decreased dose.
However, this approach is limited by the frequent sub-
stantial loss of protein specific activity associated with
polymer-conjugation. Bioconjugation commonly targets
the ε-amino group of lysine residues and/or the N-term-
inal a-amino group of the protein because they are
highly reactive and the bionconjugation reaction is mild
enough to minimize disruption of the protein structure.
Because lysine residues often assume important roles in
the formation of multi-dimensional structures and in
bonding between ligands and receptors, introduction of
polymers at these sites can potentially reduce the biolo-
gical activity of the protein[10,11]. Indeed, PEGylated
interferon, which has raised hopes as a potential cure
for hepatitis C, can only be produced as a heterogeneous
mixture with 10-30% of the anticipated activity[11].
Tumor necrosis factor-a (TNF-a), an antitumor cyto-
kine, has numerous bioactivities including direct cyto-
toxicity against tumor cells, activation of immune
antitumor response, and selective impairment of tumor-
blood vessels[12]. Thus, TNF-a has been considered as
a novel antitumor agent[13-15]. However, as a systemic
antitumor agent, very high doses of TNF-a were
required to obtain sufficient clinical responses, because
TNF-a is rapidly cleared from the circulation and also
because it becomes widely distributed to various tissues
following intravenous administration. As a result, TNF-
a with pleiotropic in vivo actions exhibited unexpected
toxic side-effects, typified by pyrexia and hypertension
[16,17]. Systemic application of TNF-a was, therefore,
abandoned despite intratumoral administration of TNF-
a showing significant antitumor effects in phase I stu-
dies[5]. Similar in vivo drawbacks are also found in the
clinical applications of other bioactive proteins[6]. Keep-
ing these problems in mind, we have devised ways to
improve the polymer-conjugation system using the
TNF-a as a model protein[18-23]. In PEGylation of
TNF-a, the specific activity of PEGylated TNF-a
decreased with the degree of PEG-modification (i.e.,
PEG modification rate). Additionally, when the PEG
modification rates are same, the bioactivity of PEGylated
TNF-a decreased with an increase in the molecular size
of the attached PEG. Thus, when bioactive proteins,
such as TNF-a, are able to stably express their activities
after binding to polymeric macromolecules, proper
attention should be paid to minimize the loss in activity
arising from the inhibition of their binding to the recep-
tor molecules due to the steric hindrance posed by the
polymeric modifier. By assessing the relationship
between the molecular weight of PEG attached to TNF-
a, degree of modification of PEG-modified TNF-a,a n d
their in vivo antitumor potency, we succeeded in mark-
edly and selectively enhancing the antitumor potency of
PEGylated-TNF-a over that of the native TNF-a.O u r
results suggest that comprehensive analysis of the rela-
tionship between the degree of modification by polymer,
molecular size, and specific activity could lead to the
development of bioconjugated proteins with increased
therapeutic value and decreased side effects.
These results suggest that PEGylation is a pragmatic
approach for developing successful therapies with drugs,
Protease
Receptor
Tissue
PEGylated
Protein
Antibody
Native protein
Glomerular 
filtration
1.  Loses bioactivity for modification of 
active site
2.  Sterically inhibits receptor binding
3.  Limits the transport from blood to tissues 
Prolongation of the plasma half-lives
1. Decrease in the renal excretion
2.  Improve in the proteolytic stability
3. Decrease in the immunogenicity
Bioconjugation of proteins increases their 
molecular size and steric hindrance.
: polyethylene glycol (PEG)
Advantage
Disadvantage
Figure 1 Bioconjugation of proteins.
Yoshioka et al. Chemistry Central Journal 2011, 5:25
http://journal.chemistrycentral.com/content/5/1/25
Page 2 of 6such as enzymes and antitumor agents. We believe that
the technique of bioconjugating drugs to a polymeric
carrier will indeed be an important technique for
expanding the clinical applications of therapeutic pro-
teins. In this context it is noteworthy that in recent
years several research laboratories around the world
have created similar polymer-conjugated bioactive pro-
teins. As a result, PEGylated granulocyte-colony stimu-
lating factor (PEG-G-CSF; PEG filgrastim), PEGylated
interferon-alpha (PEG-IFN; PEGASYS, PEG-Intron),
PEGylated asparaginase (PEG-Asp; ONCASPER), PEGy-
lated adenosine deaminase (PEG-ADA; ADAGEN) and
polystyrene-co-maleic acid-conjugated neocarzinostatin
(SMANCS) have been developed, all of which showed
marked improvement in therapeutic efficacy in compari-
son to their corresponding native forms[24-28].
A new method for site-specific PEGylation
As described above, PEGylation is limited by the fre-
quent substantial loss of protein specific activity asso-
ciated with polymer-conjugation. In addition, such
bioconjugated proteins could also consist of positional
isomers of polymeric modifiers at various sites, each one
of which may have distinct activity and other character-
istics. Random modification could produce a heteroge-
neous mixture of conjugated proteins, consisting of
different number of modifier molecules bound to var-
ious sites of the protein. As a result, functional proper-
ties of the bioconjugated proteins (such as activation, in
vivo behavior, stability) are compromised, and thus, they
could exhibit inconsistent therapeutic effects. Therefore,
to improve the polymer-conjugation technique in the
post-genome era, the pharmaceutical technology would
require a method that maintains the present efficiency
of polymer modification while simultaneously making
the site-specific modification possible. For example,
mutant proteins with free cysteine residues were created
for modification. However, introduction of cysteine resi-
dues led to protein misfolding and aggregation, resulting
in unexpected loss of activity. Furthermore, even if it
were possible to produce a cysteine mutant that retained
activity, the poor efficiency of polymer conjugation to
the thiol group made it impossible to obtain the desired
product.
To overcome this problem of PEGylation, we have
developed a strategy for site-specific PEGylation of
TNF-a (Figure 2). Because a deletion mutant of TNF-a
lacking eight residues at the N terminus retains full
bioactivity, we surmised that the N terminus of TNF-a
is not important for functiona n dm i g h tt h e r e f o r eb ea
good target for PEGylation[29]. However, TNF-a con-
tains six internal lysine residues and the amino groups
of all six of them are also targets for PEGylation. Site-
directed mutagenesis analysis have shown that Lys11
and Lys90 are vital for the bioactivity of TNF-a[30,31].
Nevertheless, if one could construct fully bioactive TNF-
a in which all the lysine residues were replaced with
other amino acids, site-specific PEGylation of the N-ter-
minus could then be carried out. This PEGylated
mutant TNF-a w o u l db ee x p e c t e dt oh a v ee x c e l l e n t
molecular uniformity and retain high bioactivity.
To construct fully bioactive TNF-a in which all the
lysine residues were replaced with other amino acids, we
employed the “molecular evolution strategy” developed
in our laboratory to artificially create functional muteins
using our phage display system[32,33]. Phage libraries
displaying polypeptides, such as naive antibodies or ran-
dom peptides, have been extensively used for identifying
specific molecules with high affinity for a target ligand
[34-36]. The advantages of a phage display system are
easy preparation of a library consisting of structural var-
iants of a polypeptide as diverse as over one hundred
million and isolation of several targeted ligand-binding
molecules from this library in few weeks. There are,
however, few studies in which the phage display techni-
que has been used to create therapeutically useful struc-
tural variants of a bioactive protein, such as a mutein
with stronger bioactivity and longer plasma half-life. To
create a lysine-deficient mutant TNF-a, a phage library
displaying mutant TNF-a lacking any lysine residue was
prepared, and it consisted of < 1 × 10
8 independent
structural variants. After two rounds of biopanning
against TNF-receptor, a lysine-deficient mutant TNF-a,
mTNF-K90R, with an in vitro bioactivity that was 6-fold
stronger than that of the wild-type TNF-a (wTNF-a)
was obtained, despite reports that some of the lysine
residues of TNF-a were essential for its bioactivity. This
mTNF-K90R had < 10-fold higher in vivo antitumor
potency and 1.3-fold lower in vivo toxicity compared to
those of wTNF-a. Therefore, the therapeutic window of
mTNF-K90R was extended by < 13-fold more than that
of the wTNF-a. Whereas multiple PEG molecules
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Page 3 of 6attached randomly to various sites of wTNF-a,o n l ya
single PEG molecule attached selectively to the N-termi-
nus of mTNF-K90R. The site-specific mono-PEGylated
mTNF-K90R (sp-PEG-mTNF-K90R) exhibited 60% spe-
cific activity of that of the mTNF-K90R, whereas the
randomly mono-PEGylated wTNF-a (ran-PEG-wTNF-
a) exhibited only 6% specific activity of that of the
wTNF-a (Table. 1). Surprisingly, the sp-PEG-mTNF-
K90R showed higher in vitro bioactivity than the wTNF-
a. Thus, these results suggest that by using this site-spe-
cific PEGylation method, we have been able to circum-
vent the problems associated with the random
PEGylation method. The sp-PEG-mTNF-K90R exhibited
an antitumor potency that was 3-fold, > 30-fold, and >
30-fold higher than the antitumor potency exhibited by
mTNF-K90R, wTNF-a and ran-PEG-wTNF-a, respec-
tively. In vivo toxicity of sp-PEG-mTNF-K90R was <
1.5-fold, 2.0-fold, and 0.6-fold lower than the in vivo
toxicity exhibited by mTNF-K90R, wTNF-a, and ran-
PEG-wTNF-a, respectively. Thus, the therapeutic win-
dow of sp-PEG-mTNF-K90R expanded by > 5-fold, 60-
fold, and 18-fold than the therapeutic window of
mTNF-K90R, wTNF-a, and ran-PEG-wTNF-a, respec-
tively. These results clearly demonstrate the advantages
of creating muteins and developing methods for site-
specific PEGylation to promote pharmacoproteomic-
based protein-drug discovery and development.
Site-specific polymer-conjugation is possible even for a
protein whose N-terminal region plays an essential role
in activation by making use of the differences between
the reaction patterns of a-Amino Groups and ε-Amino
Groups, and this could be achieved by first creating a
functional lysine-deficient mutant and then introducing
an e wl y s i n er e s i d u ei na na r e at h a ti sn o tc o n n e c t e d
with activation.
Functionalized polymer carriers as DDS
In order to deliver a bioconjugated drug to the targeted
tissue, the conjugate must demonstrate desirable phar-
macokinetic characteristics, such as plasma clearance
and tissue distribution. It is well known that the in vivo
pharmacokinetics of polymer-conjugated drugs, such as
bioactive proteins, could be markedly influenced by the
properties (such as electric charge and hydrophilic/
hydrophobic balance) of the polymeric carriers attached
to the drug surface[37,38]. Any increase in the therapeu-
tic effect of a drug bioconjugated with a polymeric
modifier could be attributed to the pharmacokinetics of
the bioconjugated drug. Therefore, prior to selecting a
polymeric modifier for bioconjugation, it is very impor-
tant to take into consideration the influence of physico-
chemical characteristics on the pharmacokinetics of the
polymer. For example, we have demonstrated that for
increased retention in blood, polyvinylpyrrolidone (PVP)
is overwhelmingly superior to PEG as a polymer carrier
[39].
These series of advances have also led us to success-
fully synthesize polyvinylpyrrolidone-co-dimethyl
maleic anhydride (PVD), a renal-targeting polymer car-
rier with pH-sensitive controlled release capability
[37,40]. PVD attaches to the amino group of a protein
at pH ≥8 and these PVD-protein conjugates gradually
releases the proteins at pH ≤ 7( F i g u r e3 ) .S i n c et h e
diseased tissues (including tissues with inflammation,
cancer, etc.) generally have lower pH levels than the
healthy ones, this means that PVD as a drug/protein
carrier would usually respond to pH levels and release
the bound drug/protein, but only in the diseased tis-
sues. Amazingly, 80% of PVD administered intrave-
nously to mice accumulated in the kidney in only a
few hours and 40% of PVD remained in the kidney for
4-days (Figure 3). The PVD was selectively taken up by
the epithelial cells of the renal tubule. It neither
showed any sign of cytotoxicity nor did it cause any
tissue damage in the kidney or elsewhere even when
administered at a high dose. I na d d i t i o n ,t h eP V Dc o n -
jugate of anti-inflammatory protein superoxide dismu-
tase (SOD) was found to be highly stable in vivo and it
accumulated at high levels in the kidney following an
Table 1 In vitro bioactivity of mono-PEGylated forms of
TNF-as
EC50 (ng/ml) (% of remaining activity)
wTNF 0.17
mTNF-K90R 0.03
ran-PEG-wTNF 2.85 (6.0%)
sp-PEG-mTNF-K90R 0.05 (60.0%)
The specific activity of the mono-PEGylated forms of TNF-a was measured by
a cytotoxic assay using LM cells in the presence of actinomycin D. EC50 is the
concentration of various PEGylated TNF-as capable of killing 50% of the cells.
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Page 4 of 6intravenous injection, bringing out the possibility that
this conjugate may have significant therapeutic value
in treating kidney inflammation.
There is no cure for renal disease, which is a serious
problem on the rise world-wide, and very few preventive
strategies are available against this disease. Bioactive
proteins, such as SOD and IL-10, were thought to be
able to prevent the progression of renal disease, but
their therapeutic potencies were too low because they
were poorly distributed in the kidney. Many researchers
have made attempts to deliver drug to the kidney. How-
ever, so far, there is no available report on delivery of
drugs specifically to the kidney. Development of a renal
delivery system that selectively carries drugs to the kid-
ney is a promising way of limiting the tissue distribution
of drugs and controlling the drug-associated toxicity.
Therefore, PVD may be a new and useful renal-targeting
drug carrier, and PVD-SOD conjugate may find clinical
applications in the effective treatment of various renal
diseases.
Conclusions
In this review, we have demonstrated the usefulness of
DDS-based technologies to selectively enhance the desir-
able therapeutic activities of bioactive proteins without
increasing their side effects. Thus, we suggest that, to
further promote the clinical applications of bioactive
proteins, it is necessary for the protein-drug innovation
system to combine 1) a method for creating mutant
proteins (muteins) with desired properties and 2) a bio-
conjugation method that generates conjugated products
with optimal properties, such as targeting capability. We
believe that this protein-drug innovation system will be
a valuable tool for the development of novel protein-
based therapies.
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